TRODELVY® (sacituzumab govitecan-hziy) HCP Site

TRODELVY® (sacituzumab govitecan-hziy) is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer (mUC) who have previously received a platinum-containing chemotherapy and either programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor. This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

TRODELVY attacks metastatic urothelial cancer (mUC) as the first antibody-drug conjugate (ADC) that binds to Trop-2.1

Based on preclinical data. May not correlate with clinical outcomes.

Trodelvy Access Support Logo

TRODELVY ACCESS SUPPORT can help you and your patients understand specific coverage and reimbursement guidelines for TRODELVY 180-mg single-dose vial. Call 1-844-TRODELVY (1-844-876-3358), Monday–Friday, 9 AM–7 PM ET.

Learn More

Download and complete the Patient Enrollment Form to get your patients started today

PD-1=programmed death receptor-1; PD-L1=programmed death-ligand 1.
Reference: 1. TRODELVY [package insert]. Foster City, CA: Gilead Sciences, Inc.; April 2021.

Medical Information

For further information, please contact:
Phone: 1-888-983-4668 or Email: